Vimarsana
Biggest News Aggregation in the World

Hematol Malign News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Hematol Malign. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Hematol Malign Today - Breaking & Trending Today

GSK : Ojjaara (momelotinib) approved in the US as the first and only treatment indicated for myelofibrosis patients with anaemia -September 15, 2023 at 04:42 pm EDT - Vimarsana News

GSK : Ojjaara (momelotinib) approved in the US as the first and only treatment indicated for myelofibrosis patients with anaemia -September 15, 2023 at 04:42 pm EDT

Published: September 15, 2023

Approval is for use in myelofibrosis patients with anaemia regardless of prior myelofibrosis therapy Nearly all myelofibrosis patients are estimated to develop...

Source: marketscreener.com
Related Topics:
United StatesNina MojasKapila VigesAnn HematolRubena MesaDrug AdministrationAtrium Health Levine Cancer CenterMyeloproliferative Neoplasms Research FoundationAmerican Society Of Clinical OncologyEuropean Hematology AssociationSenior Vice PresidentOncology Global Product StrategyExecutive DirectorChief Executive OfficerMyeloproliferative NeoplasmsResearch FoundationClinical OncologyAnnual MeetingAnnual ReportRelated AnemiaEmerging TherapeuticHematol MalignTherapeutic PotentialHigh Risk MyelofibrosisTher Clin Risk
GSK regulatory submission for momelotinib accepted for review in Japan - Vimarsana News

GSK regulatory submission for momelotinib accepted for review in Japan

Published: September 11, 2023

GSK regulatory submission for momelotinib accepted for review in Japan

Source: directorstalkinterviews.com
Related Topics:
United StatesMascarenhasj MyelofibrosisNational Library Of MedicineResearch FoundationAmerican Society Of Clinical OncologyNational Organization For Rare DisordersMinistry Of HealthClinical OncologyAnnual MeetingPrimary MyelofibrosisRare DisordersIdiopathic DisordersHematopoietic Organs Research CommitteeHematol MalignTherapeutic PotentialHigh Risk MyelofibrosisTher Clin RiskRelated AnemiaEmerging TherapeuticPractical GuideUsing Myelofibrosis Prognostic ModelsFunctional AssessmentCancer TherapyGenetic BasisIts Clinical
GSK : regulatory submission for momelotinib for the treatment of myelofibrosis accepted for review by Japanese regulator - Form 6-K -Today at 08:51 am - Vimarsana News

GSK : regulatory submission for momelotinib for the treatment of myelofibrosis accepted for review by Japanese regulator - Form 6-K -Today at 08:51 am

Published: September 11, 2023

GSK regulatory submission for momelotinib for the treatment of myelofibrosis accepted for review by Japanese regulator ● Regulatory submission included data from pivotal...

Source: marketscreener.com
Related Topics:
United Kingdom GeneralUnited KingdomCity OfUnited StatesSarah ClementsJeff MclaughlinJames DodwellSteph MountifieldCamilla CampbellMascarenhasj MyelofibrosisLyndsay MeyerNick StoneKathleen QuinnMick ReadeyJosh WilliamsTim FoleyResearch FoundationNational Organization For Rare DisordersMinistry Of HealthAmerican Society Of Clinical OncologyNational Library Of MedicineClinical OncologyAnnual MeetingAnnual ReportWest Road